



Nextrials and Vitalograph Partner to Deliver Real-Time Pulmonary Function Data Collection For Clinical Trials

Vitalograph Spirotrac[®] Centralized Spirometry System integrates with Nextrials' Prism[®] for investigational studies of novel inhalant therapies

San Ramon, CA – November 28, 2006 – Nextrials, Inc., a leader in clinical research software and services, today announced that it has established a partnership with Vitalograph[®], Ltd., a global leader in respiratory technology, to offer researchers expedited access to pulmonary function data collected during clinical trials. By tightly integrating Nextrials' Prism[®] clinical trial management system with the Vitalograph Spirotrac[®] Centralized Spirometry System, pharmaceutical, biotechnology and medical device researchers can more quickly evaluate patient pulmonary function data and monitor the changes in lung capacity or function that may occur during a clinical trial, thereby improving patient safety. Real-time access to study data also means improved workflow and better overall efficiency within an investigational study, resulting in reduced costs and time to market for new therapies.

“Like many advancements, our partnership with Nextrials is the result of an industry need,” said Marcus Garbe, Director of Vitalograph. “Sponsors requiring spirometry in inhaled therapy clinical trials need to gain immediate access to collected pulmonary function data, and Nextrials' Prism offers a cost-effective and reliable method for quickly delivering it. By integrating our technologies, Vitalograph and Nextrials can offer sponsors a unified product that delivers all relevant clinical data – including pulmonary function data – in real time, across multiple test sites and multiple studies.”

Nextrials' Prism is a fully integrated clinical trial management and electronic data capture product that includes an enhanced safety management system for monitoring ongoing safety data and reporting outcomes to regulatory authorities. Vitalograph spirometry

products are recognized worldwide as the gold standard for effective lung function testing.

“Complex clinical trials are generating an increasing amount of data that needs to be collected and quickly delivered to researchers in an organized manner,” said James Rogers, co-founder and CEO for Nextrials. “As a result, sponsors are looking for value-added methodologies that can boost patient safety, increase researchers’ access to information and more efficiently manage clinical trial resources. Nextrials’ Prism, coupled with Vitalograph’s products and technologies, is a solution designed specifically to meet the needs of inhalant therapy innovators that can help achieve these goals.”

About Vitalograph

For more than 50 years, Vitalograph has been a recognized leader in respiratory technology in the key areas of spirometry equipment for lung function diagnostics and home monitoring of peak flow for asthma and COPD management. The Spirotrac Centralized Spirometry System offers timely, quality data that is FDA 21 CFR Part 11 and HIPAA compliant, and Vitalograph spirometry equipment is established as the gold standard for Primary Care, Occupational Health and Clinical Research. Headquartered in Buckingham, U.K., Vitalograph has North American operations in Lenexa, Kansas, U.S.A.; R & D and manufacturing facilities in Ennis, County Clare, Ireland; and offices in Hamburg, Germany. For more information about Vitalograph’s products and services, visit www.vitalograph.com or contact the company at 800-255-6626.

About Nextrials, Inc.

Founded by pharmaceutical researchers in 1999, Nextrials *Innovates for Life*[™] by offering today’s most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism[®], its award-winning Electronic Data Capture (EDC) solution, has been used at over 500 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit www.nextrials.com or call 925-355-3000.

##

Contacts:
James Rogers
Nextrials, Inc.

925-355-3000

jrogers@nextrials.com

Rachel V. Berry

VOXUS, Inc.

253-853-5151, ext. 223

rberry@voxuspr.com